Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, IKEM, Videnska 1921, 140 21, Prague 4, Czech Republic.
Institute of Physiology, Charles University, Prague, Czech Republic.
Surg Endosc. 2018 Mar;32(3):1293-1302. doi: 10.1007/s00464-017-5807-3. Epub 2017 Aug 10.
Per-oral endoscopic myotomy (POEM) is becoming a standard treatment for achalasia. Long-term efficacy and the rate of post-POEM reflux should be further investigated. The main aim of this study was to analyze safety and mid-term (12 and 24 months) clinical outcomes of POEM.
Data on single tertiary center procedures were collected prospectively. The primary outcome was treatment success defined as an Eckardt score < 3 at 12 and 24 months. A total of 155 consecutive patients with achalasia underwent POEM; 133 patients were included into the analysis (22 patients will be analyzed separately as part of a multicenter randomized clinical trial).
POEM was successfully completed in 132 (99.2%) patients, and the mean length of the procedure was 69.8 min (range 31-136). One patient underwent a drainage for pleural effusion; no other serious adverse events occurred. Treatment success at 3, 12, and 24 months was observed in 95.5% (CI 89.6-98.1), 93.4% (86.5-96.8), and 84.0% (71.4-91.4) of patients, respectively. A total of 11 patients (8.3%) reported initial treatment failure (n = 5) or later recurrence (n = 6). The majority of relapses occurred in patients with achalasia type I (16.7 vs. 1.1% achalasia type II vs. 0% achalasia type III; p<0.05). At 12 months, post-POEM reflux symptoms were present in 29.7% of patients. At 3 months, mild reflux esophagitis was diagnosed in 37.6% of patients, and pathological gastroesophageal reflux was detected in 41.5% of patients. A total of 37.8% of patients had been treated with a proton pump inhibitor.
POEM resulted in greater than 90% treatment success at 12 months which tends to decrease to 84% after 2 years. More than one-third of the patients had mild reflux symptoms and/or mild esophagitis.
经口内镜下肌切开术(POEM)已成为贲门失弛缓症的标准治疗方法。需要进一步研究其长期疗效和 POEM 术后反流的发生率。本研究的主要目的是分析 POEM 的安全性和中期(12 个月和 24 个月)临床结果。
前瞻性收集单中心手术数据。主要结局是治疗成功,定义为 12 个月和 24 个月时 Eckardt 评分<3。155 例贲门失弛缓症患者行 POEM 治疗,其中 133 例患者纳入分析(22 例将作为多中心随机临床试验的一部分进行单独分析)。
132 例(99.2%)患者成功完成 POEM,手术平均时长 69.8 分钟(范围 31-136 分钟)。1 例患者行胸腔引流,无其他严重不良事件发生。3 个月、12 个月和 24 个月时的治疗成功率分别为 95.5%(89.6-98.1)、93.4%(86.5-96.8)和 84.0%(71.4-91.4)。11 例(8.3%)患者初始治疗失败(n=5)或后来复发(n=6)。大多数复发发生在贲门失弛缓症 I 型患者中(16.7% vs. 1.1%贲门失弛缓症 II 型 vs. 0%贲门失弛缓症 III 型;p<0.05)。12 个月时,POEM 术后反流症状发生率为 29.7%。3 个月时,37.6%的患者诊断为轻度反流性食管炎,41.5%的患者存在病理性胃食管反流。共 37.8%的患者接受质子泵抑制剂治疗。
POEM 治疗贲门失弛缓症的 12 个月治疗成功率超过 90%,2 年后降至 84%。超过三分之一的患者有轻度反流症状和/或轻度食管炎。